睿知中国医院研究地图
候选清单

即将招募肺癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由北京大学人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学人民医院Peking University People's Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07873086,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed primary non-squamous non-small cell lung cancer after surgery, stage IIA-IIIB (8th edition AJCC), with complete (R0) resection.

    入选标准第 3 条

    EGFR exon 19 deletion and/or exon 21 L858R mutation detected by histological or cytological testing.

    入选标准第 4 条

  3. Complete recovery from surgery at the time of initiating aumolertinib-containing adjuvant therapy; the interval between surgery and initiation of aumolertinib-containing adjuvant therapy must not exceed 10 weeks; complete postoperative wound healing; and recovery from all toxicities of prior therapy greater than CTCAE grade 1 at the start of study treatment, except for alopecia and grade 2 platinum-related neuropathy.

    入选标准第 5 条

    If there is a risk of conception, all participants (male or female) must use highly effective contraception throughout the treatment period and for 120 days after the last dose of study drug.

    入选标准第 10 条

    Receipt of any of the following: radiotherapy (preoperative, postoperative, or planned) for the current lung cancer; preoperative (neoadjuvant) platinum-based or other chemotherapy; any prior antitumor therapy other than standard platinum-based doublet adjuvant chemotherapy, including investigational therapy; prior neoadjuvant or adjuvant EGFR-TKI therapy; major surgery within 4 weeks before the first dose of study drug; or current use (or inability to discontinue at least 3 weeks before the first dose) of drugs or herbal supplements known to be strong CYP3A4 inducers. Chinese herbal medicines used solely for conditioning or nourishment do not affect enrollment.

    排除标准第 1 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

    入选标准第 6 条

  5. Diagnosis of another malignancy within 2 years before the first dose (except radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ with ≥5 years of continuous monitoring without recurrence).

    排除标准第 4 条

  6. Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days before the first dose of study drug. Women not of childbearing potential are defined as postmenopausal for at least 1 year, or surgically sterilized, or having undergone hysterectomy.

    入选标准第 9 条

    Pregnant or breastfeeding women.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07873086,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Provision of written informed consent before any study-related examination, sampling, or analysis.
  2. Age ≥18 years.
  3. Histologically confirmed primary non-squamous non-small cell lung cancer after surgery, stage IIA-IIIB (8th edition AJCC), with complete (R0) resection.
  4. EGFR exon 19 deletion and/or exon 21 L858R mutation detected by histological or cytological testing.
  5. Complete recovery from surgery at the time of initiating aumolertinib-containing adjuvant therapy; the interval between surgery and initiation of aumolertinib-containing adjuvant therapy must not exceed 10 weeks; complete postoperative wound healing; and recovery from all toxicities of prior therapy greater than CTCAE grade 1 at the start of study treatment, except for alopecia and grade 2 platinum-related neuropathy.
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  7. Adequate bone marrow and organ function: absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelet count ≥100×10⁹/L; hemoglobin >9 g/dL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; total bilirubin ≤1.5×ULN; serum creatinine ≤1.5×ULN with creatinine clearance (Cockcroft-Gault formula) ≥60 mL/min.
  8. Adequate coagulation function: international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, i.e., PT ≤19.5 seconds or INR ≤1.8.
  9. Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days before the first dose of study drug. Women not of childbearing potential are defined as postmenopausal for at least 1 year, or surgically sterilized, or having undergone hysterectomy.
  10. If there is a risk of conception, all participants (male or female) must use highly effective contraception throughout the treatment period and for 120 days after the last dose of study drug.

排除标准:Exclusion Criteria:

  1. Receipt of any of the following: radiotherapy (preoperative, postoperative, or planned) for the current lung cancer; preoperative (neoadjuvant) platinum-based or other chemotherapy; any prior antitumor therapy other than standard platinum-based doublet adjuvant chemotherapy, including investigational therapy; prior neoadjuvant or adjuvant EGFR-TKI therapy; major surgery within 4 weeks before the first dose of study drug; or current use (or inability to discontinue at least 3 weeks before the first dose) of drugs or herbal supplements known to be strong CYP3A4 inducers. Chinese herbal medicines used solely for conditioning or nourishment do not affect enrollment.
  2. Segmentectomy or wedge resection, or failure to perform lymph node dissection.
  3. Prior interstitial lung disease, drug-induced interstitial disease, or any clinically evident active interstitial lung disease; or idiopathic pulmonary fibrosis detected on baseline CT.
  4. Diagnosis of another malignancy within 2 years before the first dose (except radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ with ≥5 years of continuous monitoring without recurrence).
  5. Any unstable systemic disease, including: active infection; autoimmune disease requiring drug treatment or plasmapheresis; uncontrolled hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg); unstable angina or angina of new onset within the last 3 months; myocardial infarction (within 6 months before enrollment) or ongoing warfarin anticoagulation after cardiac stent implantation; uncontrolled asthma, chronic obstructive pulmonary disease (COPD), or pulmonary hypertension; renal insufficiency requiring dialysis; insufficient organ reserve; type 1 diabetes mellitus, or type 2 diabetes mellitus complicated by renal or cardiovascular disease or diabetic foot, or a history of ketoacidosis, lactic acidosis, hyperosmolar hyperglycemic state, or random blood glucose ≥11.1 mmol/L; and cardiac findings meeting any of the following: mean resting corrected QT interval (QTc) >470 msec from 3 ECGs (using QTcF), any clinically important abnormality of cardiac rhythm, conduction, or morphology on resting ECG (such as complete left bundle branch block, third-degree or second-degree atrioventricular block), or any factor increasing the risk of QTc prolongation or arrhythmia (such as heart failure ≥ New York Heart Association class II, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death in a first-degree relative under 40 years of age, or any concomitant medication known to prolong the QT interval).
  6. NSCLC with large cell neuroendocrine carcinoma or sarcomatoid carcinoma histology.
  7. Known allergy or hypersensitivity to aumolertinib, to compounds of similar structure, or to any of its excipients.
  8. Mixed small cell lung cancer.
  9. Pregnant or breastfeeding women.
  10. Uncontrolled nausea and vomiting, chronic gastrointestinal disease, inability to swallow the drug product, or prior major bowel resection that may affect adequate absorption of aumolertinib.
  11. Any condition that, in the investigator's judgment, makes the patient unsuitable for enrollment.

引自 ClinicalTrials.gov, NCT07873086, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07873086,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07873086